Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NutraThin claims

This article was originally published in The Tan Sheet

Executive Summary

NutraCore has agreed to permanently discontinue the establishment, performance and health claims for its Hoodia gordonii-containing Nutrathin diet pills, the National Advertising Division announces Aug. 10. The Council of Better Business Bureaus division took issue with several product claims including "Get big weight loss and fast health gains with the best slim-down supplement ever that can yield heart-health benefits too" and "No damaging health side effects known." NutraCore also instructed consumers to "take as many capsules as you need to see the results"...

You may also be interested in...



Supreme Court May Find Patent Board Judges Unconstitutionally Appointed But Favor Narrow Fix

During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.

Pro Beauty Association Opposing Fast-Tracked Bill To Deregulate Licensing In West Virginia

House Bill 2325, on a fast track in West Virginia, would bar the state’s Board of Barbers and Cosmetologists from regulating unlicensed individuals’ use or application of “generally available” cosmetic products for paying clients. PGA’s government affairs team provides detail.

Quick Listen: Scrip’s Five Must-Know Things

This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel